New BD Research Tool Helps Scientists Study Cells that are Often Key Culprits in the Development of Cancer and Infectious Diseases

BD Rhapsody™ ATAC-Seq Assay Helps Researchers Understand DNA Regulation and Enable Advancements in Precision Medicine

FRANKLIN LAKES, N.J., June 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.

Researchers worldwide are currently using innovative approaches to study multiple aspects of health and disease at a single-cell level. In the ever-evolving field of biological research, the newly launched BD Rhapsody™ Single Cell ATAC-Seq (assay for transposase-accessible chromatin using next-generation sequencing) Assay enables scientists to perform single-cell analysis of the epigenome – the set of chemical marks, or epigenetic changes, on the DNA in a single cell that holds critical clues about mechanisms of disease. Adding an epigenomic layer-view will play a crucial role in helping researchers track and understand how environmental factors impact the DNA and corresponding cell function. By gaining such knowledge about DNA, scientists can deepen their understanding of how diseases progress and apply those learnings to develop effective therapies.

"As part of our comprehensive and growing portfolio of single-cell multiomics solutions, the BD Rhapsody™ ATAC-Seq Assay, together with other recently launched BD single-cell assays, enables our customers to more deeply understand even rare cells that are often the 'key culprits' in pathologies like cancer and infectious diseases," said Steve Conly, worldwide president of Biosciences at BD. "By providing a complete portfolio of multiomics research tools, we are paving the way for scientists to tackle major challenges and develop innovative therapies leading to advancements in precision medicine. Our new single-cell multiomics assays, together with the BD Rhapsody™ portfolio of reagents and bioinformatics tools, support our aim to provide a true end-to-end ecosystem of single-cell multiomics solutions for researchers – whether at academic research, biopharmaceutical or core lab facilities."

Commercially available globally today, the BD Rhapsody™ ATAC-Seq Assay, BD Rhapsody™ TCR/BCR Next Multiomic Assay and BD Rhapsody™ Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody™ Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell research. The BD single-cell multiomics portfolio is available for purchase from BD representatives, or in some regions, through our ecommerce portal. More information is available at bdbiosciences.com or through BD sales representatives.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.

Contacts:

Media:	Investors:
Troy Kirkpatrick	Adam Reiffe
VP, Public Relations	Sr. Director, Investor Relations
858.617.2361	201.847.6927
troy.kirkpatrick@bd.com	adam.reiffe@bd.com

SOURCE BD (Becton, Dickinson and Company)

Additional assets available online: Photos (1)

https://news.bd.com/2024-06-26-New-BD-Research-Tool-Helps-Scientists-Study-Cells-that-are-Often-Key-Culprits-in-the-Development-of-Cancer-and-Infectious-Diseases